Single RNA rewires a killer parasite

What makes a parasite’s ribosome a promising drug target without harming human cells?

Leishmania is a highly adaptable parasite that cycles between two vastly different environments, an insect vector and a mammalian host. To survive these transitions, the parasite relies on a ribosome capable of adjusting its function to changing biological conditions.

In a new study led by Prof. Shulamit Michaeli, in collaboration with Nobel Laureate Prof. Ada Yonath, they provided the first comprehensive map of the chemical modifications present in the parasite's ribosomal RNA (rRNA). Their work revealed a previously unrecognized regulatory mechanism centered on a single small nucleolar RNA (snoRNA) that plays a pivotal role in ribosome biogenesis and function.

Using cryo-electron microscopy (cryo-EM), the team demonstrated that in the absence of this small RNA molecule, the parasite's ribosome undergoes significant structural alterations and loses its ability to efficiently synthesize proteins. These findings expose a fundamental structural and functional distinction between the ribosomes of Leishmania parasites and those of human cells.

Importantly, this discovery identifies a genuine molecular vulnerability within the parasite. By revealing a parasite-specific mechanism that is absent from human cells, the study highlights a potential avenue for the development of highly selective therapeutics capable of targeting the parasite while minimizing damage to host tissues.

This work provides valuable new insights into the molecular biology of parasitic pathogens and represents an important step toward the development of next-generation antiparasitic therapies.

Congratulations to Prof. Shulamit Michaeli, Prof. Ada Yonath, and the entire research team on this remarkable achievement, published in Nature Communications.

Read the full article in Nature Communications:
View the publication